In the first busy week since the August break, six companies and two SPACs entered the public market. VC-backed health and tech fared well, led by 10x Genomics (TXG) and Cloudflare (NET), while SmileDirectClub (SDC) saw its initial hype evaporate.
...read more
Satsuma Pharmaceuticals, which is developing a fast-acting dry powder nasal spray for migraines, raised $83 million by offering 5.5 million shares at $15, the midpoint of the $14 to $16 range. The company raised 10% more proceeds than expected by selling an...read more
After a month-long break, the IPO market is picking up with six deals expected to raise $2.2 billion in the week ahead. Three companies are targeting IPO valuations of $3.5 billion or more. SmileDirectClub (SDC) is the week's largest offering, raising a...read more
Satsuma Pharmaceuticals, a clinical-stage biotech developing a therapy for migraines, announced terms for its IPO on Tuesday. The South San Francisco, CA-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16....read more
US IPO Weekly Recap: Tech and life sciences fare well while SmileDirectClub falls flat in 6-IPO week
In the first busy week since the August break, six companies and two SPACs entered the public market. VC-backed health and tech fared well, led by 10x Genomics (TXG) and Cloudflare (NET), while SmileDirectClub (SDC) saw its initial hype evaporate. ...read more
Migraine biotech Satsuma Pharmaceuticals prices upsized IPO at $15 midpoint
Satsuma Pharmaceuticals, which is developing a fast-acting dry powder nasal spray for migraines, raised $83 million by offering 5.5 million shares at $15, the midpoint of the $14 to $16 range. The company raised 10% more proceeds than expected by selling an...read more
US IPO Week Ahead: IPO market is all smiles with 6 deals including SmileDirectClub
After a month-long break, the IPO market is picking up with six deals expected to raise $2.2 billion in the week ahead. Three companies are targeting IPO valuations of $3.5 billion or more. SmileDirectClub (SDC) is the week's largest offering, raising a...read more
Migraine biotech Satsuma Pharmaceuticals sets terms for $75 million IPO
Satsuma Pharmaceuticals, a clinical-stage biotech developing a therapy for migraines, announced terms for its IPO on Tuesday. The South San Francisco, CA-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16....read more